BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJ, Churchyard GJ, Grant AD. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24:1051-1055. [PMID: 20299958 DOI: 10.1097/qad.0b013e32833849df] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Pathmanathan I, Ahmedov S, Pevzner E, Anyalechi G, Modi S, Kirking H, Cavanaugh JS. TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings. Int J Tuberc Lung Dis 2018;22:596-605. [PMID: 29862942 DOI: 10.5588/ijtld.17.0758] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
2 Ahmad Khan F, Verkuijl S, Parrish A, Chikwava F, Ntumy R, El-Sadr W, Howard AA. Performance of symptom-based tuberculosis screening among people living with HIV: not as great as hoped. AIDS 2014;28:1463-72. [PMID: 24681417 DOI: 10.1097/QAD.0000000000000278] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
3 Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing latent tuberculosis in high-risk individuals: rising to the challenge in high-burden areas. J Infect Dis 2011;204 Suppl 4:S1168-78. [PMID: 21996699 DOI: 10.1093/infdis/jir449] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
4 Padmapriyadarsini C, Sekar L, Reddy D, Chitra A, Poornagangadevi N, Selvaraj M, Bhavani PK, Mothi SN, Nandagopal K, Vennila S, Tamizhselvan M, Maheshmanisha J, Agarwal U, Rewari BB, Swaminathan S. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. Indian J Med Res 2020;152:648-55. [PMID: 34145105 DOI: 10.4103/ijmr.IJMR_1582_18] [Reference Citation Analysis]
5 Menzies HJ, Moalosi G, Anisimova V, Gammino V, Sentle C, Bachhuber MA, Bile E, Radisowa K, Kachuwaire O, Basotli J, Maribe T, Makombe R, Shepherd J, Kim B, Samandari T, El-Halabi S, Chirenda J, Cain KP. Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey. Int J Tuberc Lung Dis 2014;18:1026-33. [PMID: 25189548 DOI: 10.5588/ijtld.13.0749] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
6 Teklay G, Teklu T, Legesse B, Tedla K, Klinkenberg E. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. BMC Public Health 2016;16:840. [PMID: 27543096 DOI: 10.1186/s12889-016-3525-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
7 Corbett EL, MacPherson P. Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality. Int J Tuberc Lung Dis 2013;17:1125-38. [PMID: 23928165 DOI: 10.5588/ijtld.13.0117] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
8 Stagg HR, Lipman MC, McHugh TD, Jenkins HE. Isoniazid-resistant tuberculosis: a cause for concern? Int J Tuberc Lung Dis 2017;21:129-39. [PMID: 28234075 DOI: 10.5588/ijtld.16.0716] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 13.3] [Reference Citation Analysis]
9 Mills HL, Cohen T, Colijn C. Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis. Sci Transl Med 2013;5:180ra49. [PMID: 23576815 DOI: 10.1126/scitranslmed.3005260] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
10 Jacobson KB, Niccolai L, Mtungwa N, Moll AP, Shenoi SV. "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. AIDS Care 2017;29:936-42. [PMID: 28147705 DOI: 10.1080/09540121.2017.1283390] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
11 Luabeya KK, Tameris MD, Geldenhuys HD, Mulenga H, Van Schalkwyk A, Hughes EJ, Toefey A, Scriba TJ, Hussey G, Mahomed H, McShane H, Landry B, Hanekom WA, Hatherill M. Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. Pediatr Infect Dis J 2015;34:1218-22. [PMID: 26252568 DOI: 10.1097/INF.0000000000000874] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
12 Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S. Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010. Trans R Soc Trop Med Hyg 2015;109:653-9. [PMID: 26385936 DOI: 10.1093/trstmh/trv074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Melgar M, Shiraishi RW, Tende C, Mwanza S, Mulenga J, Khondowe S, Mwakazanga D, Kapungu K, Tembo M, Nota A, Lungu P, Moore B, Podewils LJ. Assessment of the tuberculosis case-finding and prevention cascade among people living with HIV in Zambia - 2018: a cross-sectional cluster survey. BMC Public Health 2021;21:859. [PMID: 33947361 DOI: 10.1186/s12889-021-10929-z] [Reference Citation Analysis]
14 Chandra DK, Moll AP, Altice FL, Didomizio E, Andrews L, Shenoi SV. Structural barriers to implementing recommended tuberculosis preventive treatment in primary care clinics in rural South Africa. Glob Public Health 2021;:1-14. [PMID: 33650939 DOI: 10.1080/17441692.2021.1892793] [Reference Citation Analysis]
15 Rhines AS, Feldman MW, Bendavid E. Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. AIDS 2018;32:2129-40. [PMID: 30096067 DOI: 10.1097/QAD.0000000000001959] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kall MM, Coyne KM, Garrett NJ, Boyd AE, Ashcroft AT, Reeves I, Anderson J, Bothamley GH. Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study. BMC Infect Dis 2012;12:107. [PMID: 22558946 DOI: 10.1186/1471-2334-12-107] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
17 den Boon S, Matteelli A, Getahun H. Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2016;20:1065-71. [PMID: 27393541 DOI: 10.5588/ijtld.15.0908] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
18 Gersh JK, Barnabas RV, Matemo D, Kinuthia J, Feldman Z, Lacourse SM, Mecha J, Warr AJ, Kamene M, Horne DJ. Pulmonary tuberculosis screening in anti-retroviral treated adults living with HIV in Kenya. BMC Infect Dis 2021;21:218. [PMID: 33632173 DOI: 10.1186/s12879-021-05916-z] [Reference Citation Analysis]
19 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
20 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
21 Swaminathan S, Menon PA, Gopalan N, Perumal V, Santhanakrishnan RK, Ramachandran R, Chinnaiyan P, Iliayas S, Chandrasekaran P, Navaneethapandian PD. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7:e47400. [PMID: 23251327 DOI: 10.1371/journal.pone.0047400] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
22 Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnuovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One 2016;11:e0153243. [PMID: 27073928 DOI: 10.1371/journal.pone.0153243] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
23 Batt J, Khan K. Responsible use of rifampin for the treatment of latent tuberculosis infection. CMAJ 2019;191:E678-9. [PMID: 31235488 DOI: 10.1503/cmaj.190081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]